DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

THOUSAND OAKS, Calif., (March 27, 2006) – Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week ...

LOS ANGELES, April 16 (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died ...

The one bright spot in the study was that it didn't uncover any new safety issues with Aranesp. At this point, however, the anemia drug has been associated with a variety of serious side effects in ...

BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...

ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients ...

Shares of Amgen slipped slightly on Friday after the biotech giant announced that the FDA wants a new clinical trial of its monthly dose of the anemia drug Aranesp in patients with chronic kidney ...

THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results of the Phase 3 Aranesp® (darbepoetin alfa) RED-HF® (Reduction of Events With Darbepoetin Alfa ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

In view of concerns about safety, could Amgen's aggressive promotion of erythropoietin (EPO) have jeopardized its billion-dollar franchise? Amgen must be longing for the days when the only worry for ...

Johnson & Johnson posted a 13% gain in first-quarter profit on higher sales of the rheumatoid arthritis drug Remicade. Revenue from the firm’s biggest seller, the anemia treatment Procrit, rose less ...